Actually FYI, a meeting with the FDA for CLBP was requested from 1st July, whereas OTAT meeting for sr-GVHD was scheduled last month (according to SI). We don't know when we will hear from OTAT's minutes, but it doesn't seem to follow the 30days time frame. Knowing it's mesoblast, I wouldn't be surprised if the sr-GVHD minutes come in Jan and not this month.
secondly, they are for different products and will be assessed separately.
I too, have an entry price around your level. But I believe in the value of regenerative medicine. When the FDA is ready for such medicine, Mesoblast should be the first to get approval. I would compare meso in medicine to Tesla in EV. Before Tesla, everyone thinks EV will never become mainstream because of the oil&gas industry. Sounds familiar?
- Forums
- ASX - By Stock
- MSB
- Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain, page-104
-
-
- There are more pages in this discussion • 305 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.39 |
Change
-0.073(4.95%) |
Mkt cap ! $1.581B |
Open | High | Low | Value | Volume |
$1.45 | $1.46 | $1.37 | $6.448M | 4.595M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 127992 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 76732 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1271 | 1.395 |
13 | 121212 | 1.390 |
9 | 41812 | 1.385 |
13 | 183859 | 1.380 |
7 | 42118 | 1.375 |
Price($) | Vol. | No. |
---|---|---|
1.400 | 9259 | 6 |
1.405 | 16529 | 7 |
1.410 | 36041 | 8 |
1.415 | 162532 | 10 |
1.420 | 42478 | 4 |
Last trade - 13.45pm 09/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online